Holen Sie sich die Stockscreener-App
13.50
0.46%
0.0867
Schlusskurs vom Vortag:
$13.41
Offen:
$13.67
24-Stunden-Volumen:
329.88K
Relative Volume:
0.82
Marktkapitalisierung:
$173.28M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-121.02M
KGV:
-1.1986
EPS:
-11.26
Netto-Cashflow:
$-114.09M
1W Leistung:
+0.16%
1M Leistung:
-11.02%
6M Leistung:
-52.91%
1J Leistung:
-1.23%
1-Tages-Spanne:
$13.37
$14.35
1-Wochen-Bereich:
$13.20
$14.43
52-Wochen-Spanne:
$13.07
$69.97
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Firmenname
Tonix Pharmaceuticals Holding Corp
Sektor
Branche
Telefon
212-980-9155
Adresse
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
13.55 | 171.49M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.01 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.43 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.43 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.58 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.48 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-04-18 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-04-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Bestätigt | Oppenheimer | Outperform |
| 2015-11-04 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-12 | Eingeleitet | Oppenheimer | Outperform |
| 2015-02-17 | Bestätigt | ROTH Capital | Buy |
| 2014-09-29 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten
Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch - Benzinga
Tonix Pharmaceuticals reports $13.1M product revenue, $124.0M net loss for FY2025 - TradingView
Tonix Pharmaceuticals (TNXP) Reports Mixed Q4 Results with Reven - GuruFocus
Tonix Pharma earnings missed by $0.79, revenue topped estimates - Investing.com Nigeria
Tonix (TNXP) Sees Transformational Year with FDA Approval and St - GuruFocus
Tonix Pharmaceuticals Wins FDA Approval for TONMYA in Fibromyalgia and Expands CNS, Immunology, and Rare Disease Pipeline - Minichart
Tonix Pharmaceuticals (NASDAQ:TNXP) Releases Earnings Results, Misses Estimates By $0.99 EPS - MarketBeat
Tonix Pharmaceuticals Holding 2025 10-K — Revenue $13.1M, EPS (14.57) - TradingView
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - Yahoo Finance
Aug Chart Watch: What are the future prospects of Tonix Pharmaceuticals Holding CorpTrade Entry Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
TNXP: New fibromyalgia drug launch shows positive uptake; Lyme prevention antibody advances in pipeline - TradingView
Tonix presents fibromyalgia drug data at Poland conference By Investing.com - Investing.com South Africa
B2i Digital Highlights Life Sciences Virtual Investor Forum as a Featured Conference - TradingView
TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) Approved by FDA for Fibromyalgia—Tonix Pharmaceuticals Presents Positive Phase 3 Data Showing Rapid Pain Relief and Favorable Benefit-Risk Profile - Minichart
Tonix Pharmaceuticals (TNXP) Highlights New Findings on Tonmya a - GuruFocus
Tonix Pharma Highlights Positive Phase 3 Fibromyalgia Data - TipRanks
Tonix presents fibromyalgia drug data at Poland conference - Investing.com
Tonix Pharmaceuticals presents Phase 3 post hoc data showing rapid, significant pain relief with TONMYA - TradingView
Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia - The Manila Times
First new fibromyalgia drug in 15 years shows pain relief by Day 2 - Stock Titan
Tonix Pharmaceuticals (TNXP) Expected to Announce Earnings on Tuesday - MarketBeat
Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting - The Manila Times
Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting - The Manila Times
New fibromyalgia drug Tonmya cuts pain in 14-week trial - Stock Titan
Is Tonix Pharmaceuticals Holding Corp stock a hidden gem2026 Growth vs Value & High Win Rate Trade Tips - baoquankhu1.vn
Is Tonix Pharmaceuticals Holding Corp. stock safe for conservative investors2026 Sector Review & Real-Time Volume Triggers - Naître et grandir
Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development - Sahm
TNXP: Tonix Pharmaceuticals Shares Promising Results from Clinical Studies - GuruFocus
TONMYA fibromyalgia tablet under tongue bypasses first-pass liver metabolism - Stock Titan
Tonix Pharmaceuticals Announces Publication of Clinical - GlobeNewswire
Tonix Pharmaceuticals: Tonmya launches for fibromyalgia as pipeline advances toward key 2027 milestones - TradingView
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting - Sahm
Tonix Pharmaceuticals moves to Nasdaq Global Select Market - Investing.com Australia
Tonix Pharmaceuticals to Present Poster on Tonmya at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting - Bitget
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the - GlobeNewswire
Tonix Pharmaceuticals Announces Uplisting From Nasdaq Capital Market to Nasdaq Global Select Market - 富途牛牛
Tonix Pharma Uplists to Nasdaq Global Select Market - TipRanks
Tonix Pharmaceuticals announces uplisting from Nasdaq Capital Market to Nasdaq Global Select Market - marketscreener.com
Tonix Pharmaceuticals Moves Listing to Nasdaq Global Select Market - marketscreener.com
Tonix Pharmaceuticals (TNXP) Moves to Nasdaq Global Select Marke - GuruFocus
Tonix Pharmaceuticals approved to transfer listing to Nasdaq Global Select Market - TradingView
Tonix Pharmaceuticals moves to Nasdaq Global Select Market By Investing.com - Investing.com UK
Tonix Pharmaceuticals (NASDAQ: TNXP) uplists to Nasdaq Global Select tier - Stock Titan
Biotech Tonix joins Nasdaq’s top tier, which may boost visibility - Stock Titan
Avoiding Lag: Real-Time Signals in (TNXP) Movement - Stock Traders Daily
Tonix Pharmaceuticals : March 2026 Investor Deck - marketscreener.com
Tonix Pharmaceuticals to Participate in Two Investor Conferences in March - Sahm
TNXP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Tonix (TNXP) COO awarded two stock option grants under 2020 plan - Stock Titan
Tonix (TNXP) CFO granted stock options with multi-year vesting - Stock Titan
Tonix Pharmaceuticals (TNXP) CMO granted two new stock option awards - Stock Titan
Finanzdaten der Tonix Pharmaceuticals Holding Corp-Aktie (TNXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):